12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Scyllo-inositol: Phase II started

Elan began the double-blind, placebo-controlled, U.S. Phase II ELND005-BPD201 trial to evaluate oral ELND005 as an adjunctive maintenance treatment to lamotrigine or valproic acid in about 400 patients. Elan said the trial start triggered an $11 million milestone...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >